CoChat
Sign Up
Cited by 408Diabetes Treatment and ManagementDiabetes Management and ResearchPancreatic function and diabetes

The DOI matches its Crossref record.

Sulfonylureas in NIDDM

Groop, Leif C·1992·Diabetes Care
DOI 10.2337/diacare.15.6.737
Open this paper in CoChat — free account

Abstract

Sulfonylureas have represented the backbone of oral therapy in non-insulin-dependent diabetes mellitus for > 30 yr. Despite this, our knowledge about the mode of actions of these agents is limited, and the use of them is far from rational. Sulfonylureas lower blood glucose concentrations primarily by stimulating insulin secretion. The evidence for clinically significant extrapancreatic effects is scanty. Therefore, the effect of sulfonylurea is limited to patients with preserved β-cell function, with the best effect observed in the early stages of the disease. Sulfonylurea treatment is often started relatively late and is continued when the agents can no longer achieve the treatment goals. Drug dosages are increased to maximum recommended doses, although there is no evidence for a dose-response relationship between the sulfonylurea dose and its biological effect. To rationalize the use of sulfonylureas, we should ask the questions to whom, how much, and for how long? The decision to stop treatment is as important as the decision to start treatment.

Overview

Integrity signals

Registry

Crossref · 10.2337/diacare.15.6.737

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cited by

Sorted by citations

Items 301–400 of 404

Related

See all

Metadata

Authors
Groop, L. C.
Affiliations
Helsinki University Hospital (FI)
Corresponding author
Groop, Leif C
ORCID
Groop, Leif C
Venue
Diabetes Care
Publisher
American Diabetes Association
Published
1992-06-01
Volume
15
Issue
6
Pages
737-754
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
DOI
10.2337/diacare.15.6.737
OpenAlex
W1989058656
Cited by
408
References
0
Citations by year
2026: 1 · 2025: 3 · 2024: 2 · 2022: 4 · 2021: 1 · 2020: 6 · 2019: 6 · 2018: 4 · 2017: 6 · 2016: 9 · 2015: 7 · 2014: 21 · 2013: 12 · 2012: 16
FWCI
11.01
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
sulfonylureas, type 2 diabetes, oral antidiabetic therapy, insulin secretion, beta-cell function, drug dosing, treatment duration, treatment discontinuation
MeSH terms
Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Islets of Langerhans, Sulfonylurea Compounds

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review